Skeletal muscle arises from the fusion of precursor myoblasts into multinucleated myofibres 1,2 . Although conserved transcription factors and signalling proteins involved in myogenesis have been identified, upstream regulators are less well understood. Here we report an unexpected discovery that the membrane protein BAI1, previously linked to recognition of apoptotic cells by phagocytes 3 , promotes myoblast fusion. Endogenous BAI1 expression increased during myoblast fusion, and BAI1 overexpression enhanced myoblast fusion by means of signalling through ELMO/Dock180/Rac1 proteins 4 . During myoblast fusion, a fraction of myoblasts within the population underwent apoptosis and exposed phosphatidylserine, an established ligand for BAI1 (ref. 3). Blocking apoptosis potently impaired myoblast fusion, and adding back apoptotic myoblasts restored fusion. Furthermore, primary human myoblasts could be induced to form myotubes by adding apoptotic myoblasts, even under normal growth conditions. Mechanistically, apoptotic cells did not directly fuse with the healthy myoblasts, rather the apoptotic cells induced a contact-dependent signalling with neighbours to promote fusion among the healthy myoblasts. In vivo, myofibres from Bai1 2/2 mice are smaller than those from wild-type littermates. Muscle regeneration after injury was also impaired in Bai1 2/2 mice, highlighting a role for BAI1 in mammalian myogenesis. Collectively, these data identify apoptotic cells as a new type of cue that induces signalling via the phosphatidylserine receptor BAI1 to promote fusion of healthy myoblasts, with important implications for muscle development and repair.
Skeletal muscle arises from the fusion of precursor myoblasts into multinucleated myofibres 1, 2 . Although conserved transcription factors and signalling proteins involved in myogenesis have been identified, upstream regulators are less well understood. Here we report an unexpected discovery that the membrane protein BAI1, previously linked to recognition of apoptotic cells by phagocytes 3 , promotes myoblast fusion. Endogenous BAI1 expression increased during myoblast fusion, and BAI1 overexpression enhanced myoblast fusion by means of signalling through ELMO/Dock180/Rac1 proteins 4 . During myoblast fusion, a fraction of myoblasts within the population underwent apoptosis and exposed phosphatidylserine, an established ligand for BAI1 (ref. 3) . Blocking apoptosis potently impaired myoblast fusion, and adding back apoptotic myoblasts restored fusion. Furthermore, primary human myoblasts could be induced to form myotubes by adding apoptotic myoblasts, even under normal growth conditions. Mechanistically, apoptotic cells did not directly fuse with the healthy myoblasts, rather the apoptotic cells induced a contact-dependent signalling with neighbours to promote fusion among the healthy myoblasts. In vivo, myofibres from Bai1 2/2 mice are smaller than those from wild-type littermates. Muscle regeneration after injury was also impaired in Bai1 2/2 mice, highlighting a role for BAI1 in mammalian myogenesis. Collectively, these data identify apoptotic cells as a new type of cue that induces signalling via the phosphatidylserine receptor BAI1 to promote fusion of healthy myoblasts, with important implications for muscle development and repair.
Mammalian skeletal muscle is formed by the proliferation, differentiation and fusion of myogenic precursor cells (myoblasts) into multinucleated myofibres. The Dock180 protein 5 and its partner ELMO 4 function as the guanine nucleotide exchange factor to activate the GTPase Rac 6 and all three have been linked to myoblast fusion [7] [8] [9] [10] [11] [12] . The seven-transmembrane protein BAI1 (a member of the adhesiontype G-protein-coupled receptor family) mediates recognition of phosphatidylserine on apoptotic cells (Fig. 1a) , and signals through the ELMO/Dock180/Rac1 pathway 3 . We asked whether BAI1 might also play a role in myoblast fusion.
We readily detected endogenous BAI1 expression in developing embryonic day 14.5 (E14.5) mouse myofibres ( Fig. 1b ). Shifting mouse C2C12 myoblasts from growth medium to low-serum fusion medium induces formation of multinucleated, myosin-expressing myotubes 13 , and provides a quantifiable in vitro model of myogenesis 14, 15 . BAI1 was expressed in undifferentiated C2C12 myoblasts and a reproducible fourfold increase in BAI1 protein was observed in fusing cultures (Fig. 1c ). Because siRNA-mediated knockdown of BAI1 in C2C12 myoblasts was variable and inefficient, we asked whether BAI1 overexpression could provide a 'gain-of-function'. C2C12 myoblast clones stably overexpressing BAI1-green fluorescent protein (BAI1-GFP) showed enhanced myoblast fusion ( Fig. 1d, e) , and the increased fusion was seen with several independent BAI1-GFP clones. Lentivirus-based overexpression of BAI1 in C2C12 cells (maintained as heterogeneous populations) also displayed greater fusion, with a 73% increase in the fusion index (the fraction of total nuclei that are contained within the fused myotubes, see Methods) (P , 0.001, Fig. 1h ). Moreover, myotubes in cultures overexpressing BAI1 appeared longer with more nuclei compared to control cultures. Counting the number of myotubes with 2-4 nuclei (small myotubes) and $ 5 (large myotubes) confirmed that BAI1 overexpression increases the total number of myotubes and the number of nuclei per myotube (P , 0.01, Fig. 1h ).
We next tested whether BAI1-mediated C2C12 fusion was dependent on the ELMO/Dock180/Rac1 signalling module 3 . C2C12 myoblasts with knockdown of ELMO2 (the predominant isoform in myoblasts, Fig. 1f ), formed fewer myotubes and were reduced in size and nuclei content ( Fig. 1g ). To test the requirement for ELMO in BAI1-mediated enhanced fusion, we transduced a BAI1(AAA) cytoplasmic tail mutant (with the amino acids RKR changed to AAA) unable to engage the ELMO/Dock180/Rac1 module 3 . BAI1(AAA) overexpression did not increase the fusion index, total number of myotubes or nuclei per myotube ( Fig. 1h ). The fusion-promoting effect of BAI1 also depends on Rac activity, as the Rac inhibitor EHT1864 (ref. 16 ) effectively inhibited myoblast fusion in BAI1 overexpressing cells (P , 0.01, P , 0.001; Fig. 1i ). These data indicate that the membrane protein BAI1, signalling through the ELMO/Dock180/Rac1 module, can enhance mammalian myoblast fusion.
During phagocytosis, BAI1 on phagocytes recognizes phosphatidylserine, a near-universal marker exposed on the surface of apoptotic cells; previous studies have indicated that transient externalization of phosphatidylserine is necessary for myoblast fusion 17, 18 . Myoblast fusion was strikingly inhibited by masking phosphatidylserine in fusing cultures, using either a phosphatidylserine binding domain of BAI1 (GST-TSR) 3 or a phosphatidylserine-specific antibody fragment (Supplementary Fig. 1a, b ). We also found that a significant fraction of C2C12 myoblasts underwent cell death within 24 h after switching to fusion medium (associated with rounding up and detachment from the plate). Such cells displayed several known features of apoptosis, with 17% of cells positive for annexin V, 9% positive for the apoptosis indicator stain TO-PRO-3 (which enters apoptotic cells through caspaseactivated channels 19 ), and 9% positive for active caspase-3 (P , 0.01, P , 0.05; Fig. 2a ). These percentages may be an underestimation due to the unavoidable loss of apoptotic cells during the staining protocols. We also analysed paraspinal muscle tissue at different stages of embryogenesis, and could readily detect apoptotic cells labelled with cleaved caspase 3 (73.8 6 32.0 per mm 2 ) that were in contact with E14.5 myofibres ( Fig. 2b, left panel) . Several of these apoptotic cells also displayed blebbing ( Fig. 2b , right panel). Of note, E14.5 is also the stage when we observed a strong BAI1 staining of developing myofibres (Fig. 1b) .
We next tested whether apoptosis was required for myoblast fusion. Adding z-VAD-FMK (zVAD), a pan-caspase inhibitor that blocks apoptosis, potently inhibited myoblast fusion (51% decrease in fusion index, P 5 0.0002; Fig. 2c ). Similar results were observed with another pan-caspase inhibitor, Q-VD-OPH (Q-VD). Supplementing insulintransferrin-selenium to fusion medium enhances myoblast fusion, yielding large, sheet-like myotubes within 24-48 h ( Supplementary  Fig. 1c ). Caspase inhibition also potently inhibited insulin-transferrinselenium-enhanced fusion (67% decrease, P , 0.0001; Supplementary  Fig. 1c ). zVAD blocked fusion of BAI1-GFP-overexpressing cells, indicating that the fusion-promoting effect of BAI1 also depends on cell death within fusing cultures ( Fig. 2d ).
Concerns that the caspase-inhibitor-mediated block of myoblast fusion could have arisen due to unintended, non-specific effects were overcome when the removal of zVAD from myoblast cultures, even after treatment for 5 days, re-initiated fusion (data not shown). Moreover, zVAD inhibition of myoblast fusion depended on the time when the myoblasts were exposed to the drug; zVAD was far less effective when added to C2C12 cells already switched to fusion medium and after the appearance of floating/apoptotic cells ( Fig. 2e ). These observations suggest that the emergence of apoptotic myoblasts in fusing cultures is essential for normal myoblast fusion.
Myogenin (MyoG) is an essential basic-helix-loop-helix myogenic transcription factor involved in the development of skeletal muscle in vivo 20 . Caspase inhibition did not block the approximate 60-fold upregulation of the Myog transcript ( Supplementary Fig. 2 ), even though both zVAD and Q-VD effectively blocked expression of myosin, another well-known differentiation marker ( Fig. 2c and Supplementary  Fig. 1c ). This suggests that caspase inhibition does not block all differentiation steps, and that caspase-mediated apoptosis during myoblast fusion is required either downstream or parallel to MyoG.
We investigated whether adding apoptotic myoblasts could rescue fusion in zVAD-treated cultures. We collected the floating/apoptotic myoblasts from fusing cultures without zVAD, gently resuspended them in fresh fusion medium containing zVAD, and added them to zVAD-treated fusing cultures (see schematic in Fig. 3a ). Adding apoptotic myoblasts effectively rescued zVAD-inhibited myoblast fusion, 
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with a 149% increase in the fusion index (P , 0.01, Fig. 3b ). The added apoptotic myoblasts exposed phosphatidylserine (Supplementary Fig. 3a ), but did not attach to the tissue culture plate, nor was there fusion between the apoptotic cells ( Supplementary Fig. 3b ); thus, the simple increase in cell density or adherence could not explain the fusion-promoting effect. Notably, supernatants from fusing myoblast cultures (passed through a 0.2-mm filter) failed to rescue zVADinhibited fusion (Fig. 3b ). Adding one apoptotic myoblast per two viable myoblasts could maximally rescue the zVAD-inhibited fusion ( Supplementary Fig. 3c ), whereas adding too many dying myoblasts was less effective. Consistent with the observation that phosphatidylserine exposure is necessary for myoblast fusion, masking phosphatidylserine on apoptotic myoblasts (with GST-TSR, ref.
3) failed to rescue fusion (P , 0.001, Supplementary Fig. 3d ). When we tested whether apoptotic myoblasts delivered a unique signal or if any apoptotic-cell type could stimulate fusion, apoptotic primary mouse thymocytes also rescued zVAD-inhibited myoblast fusion (P , 0.001, Supplementary  Fig. 4c ). These data further indicated that caspase inhibition itself does not have a non-specific effect, and that myoblasts can fuse in the presence of zVAD if provided with apoptotic cells. Collectively, these observations suggest that apoptotic myoblasts are necessary to promote myoblast fusion, requiring phosphatidylserine-dependent cellcell contact between apoptotic and viable myoblasts.
Normally, fusion is deficient or absent in C2C12 myoblasts cultured in growth medium (Fig. 3c ). Strikingly, adding apoptotic myoblasts to the myoblast cultures in growth medium stimulated fusion (70% increase in the fusion index, P , 0.05; Fig. 3c ). This effect of apoptotic myoblasts was again dependent on phosphatidylserine exposure ( Fig. 3c ). Because myoblasts in growth medium continue to divide with no apparent cell death, these cultures had more nuclei at the end of the assay, artificially lowering the fusion index values. However, counting the number of myotubes containing 2-4 nuclei (small myotubes) and $ 5 nuclei (large myotubes) revealed that apoptotic myoblasts significantly promoted myotubes with $ 5 nuclei (P , 0.001, Fig. 3c ). This fusion-promoting effect of apoptotic cells in growth medium was not caused by lowering nutrients in the culture medium (mimicking low mitogen fusion medium conditions); adding 'viable' T lymphocytes, which proliferated and consumed nutrients from the culture medium did not promote fusion, whereas apoptotic lymphocytes triggered fusion (P , 0.001, P , 0.01; Supplementary Fig. 4b ). We then asked whether these observations might extend to primary human myoblasts. Primary human myoblasts readily fused and formed myotubes when cultured in fusion medium but not in growth medium (Fig. 3d, left) . Adding apoptotic C2C12 myoblasts stimulated fusion of primary human myoblasts in growth medium, with a 170% increase in the fusion index (P , 0.05, Fig. 3d ). Thus, dying cells could stimulate mouse and human myoblasts to fuse and form myotubes.
To address the function of BAI1 in myoblast fusion in vivo, we generated Bai 2/2 mice using embryonic stem cells with an exon trap mutation of exon 2. We compared myofibres from the tibialis anterior (TA) muscle of 12-week-old male Bai1 1/1 versus Bai1 2/2 littermate mice ( Fig. 4a ). Although Bai1 2/2 muscles did contain fully formed myofibres, they contained smaller-sized fibres as well as clusters of very small fibres ( Fig. 4b, arrowheads ). We took an unbiased approach to quantitate the cross-sectional areas (CSA) of each myofibre using the CellProfiler software tool 21 , and plotted the frequency distribution of the myofibres (Fig. 4c ). The TA muscles of the Bai1 2/2 mice were skewed towards smaller myofibres compared to control littermates. Classifying the myofibres as either small (,1,500 mm 2 ) or large (.1,500 mm 2 ), the Bai1 2/2 TA muscle had a greater proportion of small myofibres and significantly fewer large myofibres, suggesting a need for BAI1 in larger myofibre formation (P , 0.05, n 5 5-8 mice; Fig. 4c, right) . Additionally, the average myofibre CSA of Bai1 2/2 mice a, Schematic depicting the adding back of apoptotic myoblasts. b, Apoptotic myoblasts or cell-free supernatants were added to C2C12 cells treated with zVAD in fusion medium. Nuclei (Hoechst, cyan) and myotubes (anti-myosin antibody, red) were labelled, and six fields analysed per treatment group for each experiment (**P , 0.01, ***P , 0.001). c, C2C12 cultures were maintained in fusion medium (FM), growth medium (GM), or GM plus apoptotic C2C12 cells pre-incubated with either control GST protein or GST-TSR (to mask phosphatidylserine) and analysed as above (*P , 0.05, ***P , 0.001). Note the increase in myotubes with $ 5 nuclei (large myotubes) (***P , 0.001). d, Human primary skeletal myoblast cultures were maintained in FM, GM, or GM with apoptotic C2C12 myoblasts and analysed as above (*P , 0.05, ***P , 0.001). All data represent at least three independent experiments.
Error bars indicate s.d. and scale bars represent 50 mm.
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(per mouse) was again significantly reduced compared to Bai1 1/1 littermates (P , 0.05, n 5 5-8 mice; Fig. 4d ). It is notable that Bai1 2/2 mice did develop major skeletal muscle tissues, possibly due to the continued expression of the Bai1 homologues Bai2 and Bai3 (as seen in the TA muscle, P , 0.05, n 5 5 mice per genotype; Supplementary Fig. 5a ). These data indicated a requirement for BAI1 in optimal myofibre development in vivo.
To test whether BAI1 might influence muscle repair and regeneration, we used the cardiotoxin (cdx)-induced muscle injury and repair model 22 (Supplementary Fig. 5b ). After cardiotoxin injection into TA muscles of control and Bai1 2/2 mice, we analysed regenerating fibres after 14 days (shown in images of Fig. 4e ). Focusing our analysis on the regenerated fibres, the average myofibre cross-sectional areas of the Bai1 2/2 mice were reduced compared to the Bai1 1/1 littermates (P , 0.05, n 5 3 mice; Fig. 4f and Supplementary Fig. 5c ). Using centralized nuclei number per myofibre to calculate the in vivo fusion index (see Methods 23 ), the Bai1 2/2 mice displayed a 31% reduction compared to littermate controls (P , 0.01, n 5 6-8 mice; Fig. 4e, right) . These results demonstrated a requirement for BAI1 in the optimal fusion and regeneration of myofibres after muscle injury.
Because BAI1 is a phagocytic receptor for apoptotic cells 3 and apoptotic cells influence myoblast fusion, an interesting possibility was that engulfment of dying myoblasts by healthy myoblasts contributed to myoblast fusion. Alternatively, engagement by the dying myoblasts with the healthy myoblasts might have provided signalling cues (not contingent on phagocytosis) that contributed to fusion. We found that the healthy myoblasts could engulf apoptotic myoblasts in vitro, an observation not reported previously (Fig. 4g) . We next used time-lapse microscopy to investigate the fate of apoptotic myoblasts emerging during fusion and what might happen to the nuclei of apoptotic cells (although nuclei of apoptotic cells are damaged and unlikely to directly contribute to the multinucleated myotubes). The apoptotic myoblasts, which were labelled by adding the viability dye TO-PRO-3 to the fusion medium, appeared to not be engulfed by nascent myotubes; rather, TO-PRO-3-stained cells remained in close contact with the newly forming myotubes ( Fig. 4h, Supplementary Fig. 6 and Supplementary Video 1). This close association (without obvious phagocytosis) was confirmed with a second viability dye eFluor; 62% of dying myoblasts were in close proximity (but not within) myosin-positive myotubes, and 94% of myotubes were in close proximity to dying myoblasts (Fig. 4i ). However, these data do not rule out additional roles for phagocytosis during myoblast fusion (perhaps for acquiring energy). Notably, we could detect actin polymerization at some of the contacts between apoptotic cells and fusing myotubes ( Supplementary Fig. 7) .
The data presented here identify a new and unexpected positive role for the phosphatidylserine receptor BAI1 in promoting fusion of skeletal myoblasts to form myotubes. Lowered expression of Bai1 was observed in transcriptome analyses of muscles from Duchenne muscular dystrophy patients 24 . Additionally, expression levels of the genes that encode ELMO2 and Dock180 are altered in skeletal muscle disorders [24] [25] [26] [27] . Thus, identification of BAI1 as a novel promoter of myoblast fusion, and the link between ELMO/Dock180/Rac1 signalling pathway and myoblast fusion 7-12 has relevance for mammalian skeletal muscle development and muscle disorders.
These data also identify the interaction between apoptotic and healthy myoblasts as a new type of fusion cue that in turn promotes fusion between healthy myoblasts. Apoptotic cells appear to contact the viable fusing myoblasts/myotubes without fusing with them, suggesting an interaction distinct from the one between a fusion competent myoblast and a founder cell seen in Drosophila melanogaster 1 . Interestingly, Casp3 2/2 mice have been reported to be smaller in size with reduction of total skeletal muscle mass compared to their control littermates, and this phenotype was linked to cleavage of MST1 kinase in fusing cells, suggesting additional promyogenic roles for caspase 3 (ref. 28) . Because cell death within the muscle is often associated with weight training and strength conditioning exercises that promote muscle mass 29 , further studies targeting the triggering of BAI1 or other phosphatidylserine receptors in stimulating muscle growth could be beneficial for promoting recovery after muscle injuries.
Although apoptosis and cell clearance have been studied for many years, dying cells are generally considered a nuisance that need to be 1,000 1,500 2,000 2,500 3,000 Supplementary Fig. 6 and Supplementary Video 1 for additional frames. i, Apoptotic myoblasts (viability dye, red) are often in proximity but not within the fusing myoblasts or myotubes (anti-myosin, green). Nuclei are stained blue (Hoechst). Red boxes are shown in higher magnification (right). Scale bar, 100 mm.
Error bars indicate s.e.m., and scale bars represent 50 mm, unless otherwise indicated.
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removed quickly. The concept that the body may use cell death not only to rid itself of unwanted cells, but also to use them to beneficially regulate differentiation adds an important dimension to considering cell turnover within tissues and organisms. Activated lymphocytes and other cell types are known to transiently expose phosphatidylserine in non-apoptotic contexts 30 . An intriguing possibility is that these transient phosphatidylserine exposures, through cell-cell contact (for example, in germinal centres of lymph nodes during immune responses), might be involved in differentiation events in other tissues.
METHODS SUMMARY
Cell culture and myoblast fusion assay. C2C12 murine skeletal muscle myoblasts were maintained at sub-confluent densities in DMEM with 20% FBS. Normal human primary skeletal muscle myoblasts (Clonetics) were maintained at subconfluent densities in defined SkGM-2 medium (Clonetics). Confluent myoblasts on LabTek II Permanox 2-chamber slides (Nunc) were induced to undergo fusion by switching to fusion medium (DMEM with 2% heat-inactivated horse serum). Myoblasts/myotubes were washed, fixed and stained with anti-myosin antibody (see Methods). ImageJ cell counter plugin software was used to quantitate nuclei number. The fusion index (see Methods) was calculated for each of six random fields that were analysed for each sample per experiment.
In vivo myofibre analysis. Embryonic stems cells carrying the exon trap mutation of exon 2 of Bai1 locus were used to generate Bai1 2/2 null mice. TA muscles from Bai1 2/2 and wild-type littermates (gender matched) were dissected and processed into paraffin blocks. 5-mm sections were stained with H&E and at least five fields were captured for each mouse section. The CSA of each myofibre per field was quantitated using CellProfiler 21 ; output files were then screened for accuracy in a blinded fashion. To quantitate myofibre fusion after injury, the in vivo fusion index (the percentage of TA myofibres containing multiple central nuclei versus the total number of myofibres) was calculated for each field 23 .
Full Methods and any associated references are available in the online version of the paper.
METHODS
Cell culture and myoblast fusion assay. C2C12 murine skeletal muscle myoblasts (American Type Culture collection) were maintained at sub-confluent densities in growth medium (DMEM buffer supplemented with 20% heat-inactivated FBS) at 8.5% CO 2 at 37 uC. Normal human primary skeletal muscle myoblasts (Clonetics) were maintained at sub-confluent densities in defined SkGM-2 medium (Clonetics) at 5% CO 2 at 37 uC. Myoblast fusion (of both C2C12 and primary human myoblasts) was induced by rinsing 70-80% confluent cultures once with PBS and switching them to fusion medium (DMEM supplemented with 2% heatinactivated horse serum). Fusion medium was replaced every 24 h for a total of 72 h, unless specified otherwise. Where indicated, zVAD-FMK (100 mM, Enzo Life Sciences), Q-VD-OPH (100-150 mM, SM Biochemicals), Dead-Cert imab6 fragment (100 mg ml -1 , Immunosolv), or GST-tagged BAI1 TSR (100 mg ml 21 ) 3 was added to cultures 24 h before switching to fusion medium and maintained throughout the experiment. When indicated, EHT 1864 (10 mM, Sigma-Aldrich) or insulin-transferrin-selenium (13, Gibco) was added at the same time as fusion medium and maintained throughout the experiment. Fluorescence microscopy and quantitative analysis of fusion. To measure fusion, myoblasts were plated in growth medium on 2-chamber LabTek II Permanox chamber slides (Nunc) at 1 3 10 5 cells per well (C2C12) or 7.5 3 10 4 cells per well (Human primary skeletal muscle myoblasts and C2C12 in GM in addingback experiments). Myoblasts were induced to undergo myogenic differentiation as described above. Myoblasts/myotubes were washed and fixed with 4% paraformaldehyde in PBS for 20 min at room temperature and permeabilized in 0.2% Triton X-100, 0.1% citrate in PBS for 5 min at room temperature. After blocking with 2% BSA/PBS, cells were stained with anti-myosin antibody (Skeletal, Fast; Sigma-Aldrich) at 1:1,000 dilution overnight at 4 uC. After washing with PBS, cells were incubated with Alexa Fluor 647-labelled secondary antibody (Invitrogen) at 1:400 for 1 h at room temperature, stained with Hoechst 33342 (1 mg ml 21 , Invitrogen) for 2 min at room temperature, washed and then mounted with ProLong Gold (Invitrogen). Microscopy was performed using the Axio Imager 2 with Apotome (Carl Zeiss) and AxioVision software for analysis.
To quantitate in vitro myoblast fusion, the fusion index was determined as described previously 15 . Briefly, fluorescent images of six random fields were captured for each sample per experiment. ImageJ cell counter plugin software was used to quantitate nuclei number. The fusion index (the percentage of nuclei within myosin positive cells versus the total number of nuclei) was calculated for each field. Fusion indices from each field per sample were compiled and are depicted as the mean plus the standard deviation (s.d.). In addition, the number of myosin positive myotubes per field with 2-4 nuclei (small myotubes) and 5 or more nuclei (large myotubes) were recorded as another means to quantify myoblast fusion. Flow cytometric analysis for apoptosis. To measure phosphatidylserine exposure, floating and adherent C2C12 myoblasts or thymocytes were stained with APC-conjugated annexin V diluted 1:20 in annexin V-binding buffer (eBioscience) for 10 min at room temperature. Cells were washed, resuspended in annexin V-binding buffer and assessed by flow cytometry. To measure selective membrane permeability during apoptosis, C2C12 cultures at the indicated time points after addition of fusion medium were treated with TO-PRO-3 (1 mM, Molecular Probes) for 20 min at 37 uC. Cells were washed in PBS, resuspended in PBS with 0.5% BSA and assessed by flow cytometry. To measure caspase-3 activation, floating and adherent C2C12 myoblasts were fixed and permeabilized with Cytofix/Cytoperm solution (BD Biosciences) and stained with Alexa Fluor 488-conjugated cleaved caspase-3 antibody diluted 1:20 in Cytoperm solution (Cell Signaling) for 20 min on ice. Cells were washed in Cytoperm solution, resuspended in PBS with 0.5% BSA and assessed by flow cytometry. Rescue of myoblast fusion. C2C12 cells were grown to 80% confluence in 15-cm tissue culture plates, after which they were induced to undergo myogenic differentiation as described previously. After 24 h in fusion medium, the floating/dying myoblasts were collected at 115 g for 5 min and resuspended gently into fresh fusion medium or growth medium. Unless specified otherwise, dying C2C12 myoblasts were added at a 1:1 ratio to plated, viable myoblasts at the time of the initial switch to fusion medium, or the myoblasts were ,80% confluent if maintained in growth medium. The apoptotic myoblasts were spun down onto the viable myoblasts for 2 min at 30 g. This treatment was repeated each following day for 3 days in total. Where indicated, dying myoblasts were pre-treated with GST-tagged BAI1 TSR (100 mg ml -1 ) for 1 h at 37 uC before adding them to fusing cultures.
Thymuses were isolated from 4-5 week old mice and crushed through a 70-mm strainer to achieve single cell suspensions. Thymocytes were induced to undergo apoptosis by anti-Fas antibody treatment as described previously 19 . Briefly, 10 3 10 6 thymocytes were collected and resuspended in C2C12 fusion medium with Protein-G (2 mg ml 21 , Sigma) and anti-CD95 (Fas) antibody (5 mg ml 21 , BD Biosciences). Two hours after treatment with anti-Fas, 5 3 10 6 apoptotic thymocytes were added to confluent, zVAD treated C2C12 myoblasts and spun down for 2 min at 30g. This treatment was repeated each following day for 3 days total.
Jurkat T cells (E6.1) were induced to undergo apoptosis by ultraviolet irradiation as described previously 19 . Briefly, Jurkat cells were collected at 115 g for 5 min, resuspended in C2C12 growth medium and irradiated with 1,500 mJoules of ultraviolet irradiation. Four hours after irradiation (recovery period), 4 3 10 6 ultraviolet-treated or viable Jurkat cells were added to ,80% confluent plated, viable C2C12 myoblasts and spun down for 2 min at 30g. This treatment was repeated each following day for 3 days in total.
Immunoblotting. C2C12 myoblasts were induced to fuse as described above and were collected at indicated time points after the switch to fusion medium. Cells were lysed and total protein was quantified for each sample lysate using the D c Protein Assay (Bio-Rad). Samples were analysed by SDS-PAGE and immunoblotted. To detect BAI1 expression, a custom polyclonal rabbit antisera against a conserved carboxy-terminal epitope was generated by injecting rabbits with a KLH-linked peptide (Novus Biologicals). Antibodies were used after one round of affinity purification on peptide columns. Peptide competition experiments and immunoblotting demonstrating antibody specificity were previously reported 31 . BAI1 antibody was used at a concentration of 1 mg ml 21 in 5% milk/TBS-T for immunoblotting in these studies. Processing and immunostaining of mouse embryonic tissue. C57BL/6 mice were obtained from the Jackson Laboratories. All animal procedures were performed as per protocols approved by the University of Virginia Animal Care and Use Committee.
For the detection of BAI1 in vivo, E14.5 mouse tissues were fixed by immersion in 4% paraformaldehyde in PBS and processed into paraffin blocks. 5-mm sections were processed for immunohistochemistry using standard techniques. Immunoperoxidase detection was performed using the ImPress polymeric peroxidase reagent (Vector), according to the supplier's instructions. The chromogen used was diaminobenzidine (Dako S3000) 1 mg ml 21 in PBS plus 0.02% hydrogen peroxide applied for 5 min and sections were counterstained with haematoxylin.
For the detection of apoptotic cells in vivo, embryos were collected in PBS and subsequently fixed in 4% paraformaldehyde in PBS for 24 h at 4 uC. Whole embryos were processed for paraffin infiltration by standard methods. Immunohistochemistry was performed on 8-mm-thick paraffin sections using standard techniques. Primary antibodies used were: rabbit polyclonal anti-cleaved caspase 3 (1:100, Cell Signaling Technology), mouse monoclonal anti-actin (1:100, Sigma-Aldrich, clone AC-15). Immunofluorescence detection was performed using Alexa Fluor 488 and Alexa Fluor 546-conjugated secondary antibodies, diluted 1:2,000 (Invitrogen). Images were acquired with an Olympus BX40 upright microscope and a Scion Firewire charge-coupled device (CCD) camera (Scion). The entire paraspinal muscles of four sample sections were analysed for the presence of cleaved caspase 3 1 bodies. Stable transfections. For the generation of BAI1-GFP myoblasts, low-passage C2C12 myoblasts grown to 20-40% confluency in a 6-well dish were transfected with 20 mg of plasmid (pEBB-BAI1-GFP) plus 5 mg of selection plasmid (pA-Puro) or selection plasmid alone using Lipofectamine 2000 (Invitrogen). Two days after transfection, the wells were replated into 10-cm 2 tissue culture plates and puromycin dihydrochloride (5 mg ml 21 , Sigma-Aldrich) was added to cultures. GFPpositive puromycin-resistant, or puromycin-resistant only control single-colony clones were isolated. Clones were analysed for BAI1-GFP expression via flow cytometry and epifluorescence microscopy.
For the generation of ELMO2-knockdown shRNA, a 19-mer target sequence was identified using Dharmacon siDESIGN Center (AGCGCAAGGCCATG TATAC), and antisense oligos were generated using the pSicoOligomaker 1.5 program. The oligos were annealed and ligated into the pSicoR-GFP plasmid (Addgene), which co-expresses GFP for detection of expression. Low-passage C2C12 myoblasts grown to 30-40% confluency in a 6-well dish were transfected with 4 mg of ELMO2 or control shRNA plasmid along with 1 mg of selection plasmid (pA-Puro) using Lipofectamine 2000 (Invitrogen). The next day, the cells were replated into 10-cm 2 tissue culture plates and puromycin (5 mg ml 21 , Sigma-Aldrich) was added to cultures. The puromycin-resistant cells were maintained as a heterogenous population. To achieve a pure culture of ELMO2 or control shRNA-expressing myoblasts, the populations were cell-sorted on the basis of GFP expression using an iCyt Reflection cell sorter (Sony Biotechnology). Lentiviral-mediated transduction. High-titre lentivirus containing wild-type human BAI1, a mutant BAI1(AAA) or empty vector complementary DNA was generated using ViraPower HiPerform lentiviral expression system (Invitrogen) with several modifications. The attB sites and lacZ in pLenti6.3/V5-GW/lacZ were replaced with a multi-cloning site, and wild type or mutant BAI1 cDNA was inserted. In place of 293FT cells, lentivirus was produced in Lenti-X 293T cells (Clontech) transfected using calcium phosphate (Promega), and supernatants containing live virus were concentrated with Lenti-X Concentrator (Clontech) RESEARCH LETTER
